• Policy
• Asciminib's domestic approval is at a quick step
• by Lee, Tak-Sun Dec 6, 2021 05:53am

• Policy
• Companies in a dilemma over who bears losartan recall cost
• by Lee, Tak-Sun Dec 3, 2021 05:55am

• Policy
• MFDS reviews Pfizer COVID-19 vaccine used without dilution
• by Lee, Tak-Sun Dec 2, 2021 05:54am

• Policy
• Did Mooncare truly reinforce coverage for rare diseases?
• by Eo, Yun-Ho Dec 1, 2021 05:57am

• Policy
• 30 new drug items reimbursed or extended coverage this year
• by Kim, Jung-Ju Nov 30, 2021 05:52am

• Policy
• Review period & material improved for COVID-19 Txs, etc.
• by Lee, Jeong-Hwan Nov 29, 2021 05:58am

• Policy
• A new pre-approval system for Ultomiris was established
• by Lee, Hye-Kyung Nov 29, 2021 05:58am

• Policy
• Winner of pricing suits will be compensated for damages
• by Kim, Jung-Ju Nov 26, 2021 05:54am

• Policy
• Cost bearer in debate ahead recall of some losartan products
• by Lee, Tak-Sun Nov 26, 2021 05:53am

• Policy
• All agreed to the legislation of the CSO reporting system
• by Lee, Jeong-Hwan Nov 26, 2021 05:53am